期刊
COMPLEMENTARY THERAPIES IN CLINICAL PRACTICE
卷 42, 期 -, 页码 -出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.ctcp.2020.101291
关键词
Chromium; Cardiovascular diseases; Myocardial infarction; Inflammation; Meta-analysis
The systematic review found that chromium supplementation significantly reduced levels of certain inflammatory markers but had an insignificant effect on interleukin-6. Overall, the results suggest that chromium supplementation may improve biomarkers of inflammation related to myocardial infarction.
Background: The objective of this systematic review is to assess the relationship between chromium supplementation and inflammatory biomarkers levels (hs-CRP, TNF-alpha, IL-6) as risk factor for cardiovascular diseases. Recent studies raise questions regarding the potential of chromium supplementation to decrease the blood-levels of inflammatory markers, lowering cellular oxidative stress as markers of myocardial infarction; however, the results of the researches are inconclusive. Methods: The following databases including PubMed, Scopus, Cochran Library and Embase databases were systematically searched until April 2020. Analysis was performed using random-effect model. Results: The pooled findings for biomarkers of inflammation showed that chromium supplementation significantly reduced serum high-sensitivity C-reactive protein (hs-CRP) (WMD:-0.87 mg/dL, 95% CI:-1.49,-0.26), and tumor necrosis factor-alpha (TNF-alpha) (WMD:-0.97 pg/ml; 95% CI:-1.92,-0.01) and chromium insignificantly reduced interleukin-6 (IL-6) (WMD:-0.45 pg/ml, 95% CI:-1.18, 0.29). Conclusion: Overall, the results of this systematic review and meta-analysis imply that chromium supplementation may help to improve biomarkers of inflammation as markers of myocardial infarction.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据